Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells.

Revenue(FY, 2017)

$327 K

Market capitalization(2018-07-11)

$940.3 M

Type

Public

Berkeley, US

Founded

1996

Size (employees)

251 (est)

Website

dynavax.com

Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, US

Report incorrect company information

Dynavax Technologies Corporation Office Locations

Open Map View

Dynavax Technologies Corporation has an office in Berkeley

Berkeley, US (HQ)

100 2929 Seventh Street

Show all (1)

Report incorrect company information

Dynavax Technologies Corporation Financials and Metrics

Dynavax Technologies Corporation Revenue

Dynavax Technologies Corporation's revenue was reported to be $327 k in FY, 2017

Summary

USD
Revenue (Q1, 2018)	165 k
Net income (Q1, 2018)	(39 m)
EBIT (Q1, 2018)	(38.3 m)
Market capitalization (11-Jul-2018)	940.3 m
Closing share price (11-Jul-2018)	15.1
Cash (31-Mar-2018)	36.1 m
EV	1 b

Dynavax Technologies Corporation's current market capitalization is $940.3 m.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	11.3 m	11 m	4.1 m	11 m	327 k
Revenue growth, %		(2%)	(63%)	173%
General and administrative expense	25.9 m	17.4 m	22.2 m	37.3 m	27.4 m
R&D expense	50.9 m	84.6 m	86.9 m	84.5 m	65 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Revenue		3.5 m	3 m	2.2 m	627 k	1.6 m	1.2 m	942 k	2.6 m	162 k	148 k	105 k	165 k
General and administrative expense	5.8 m	4.2 m	4.1 m	4.1 m	4.9 m	5.1 m	5.5 m	8.2 m	9.2 m	11.8 m	6.5 m	5.6 m	16.9 m
R&D expense	11.8 m	13.2 m	23.6 m	28.1 m	22.2 m	19.7 m	24.1 m	20.1 m	22.8 m	23.2 m	16.3 m	14.8 m	19 m
Operating expense total	18.5 m	17.5 m	27.9 m	32.3 m	27.1 m	24.8 m	29.6 m	28.2 m	31.9 m	35 m	25.6 m	20.4 m	38.5 m

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	23.1 m	49.5 m	44.8 m	24.3 m	26.6 m
Accounts Receivable	1.6 m	727 k	1.4 m
Inventories	1.4 m	4.1 m	2.4 m	6.8 m	312 k
Current Assets	192.4 m	127.4 m	199.9 m	89.6 m	198 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	12.2 m	26.8 m	17 m	19.7 m	14.7 m	36.5 m	103 m	38.9 m	24.8 m	23 m	21.5 m	37.7 m	36.1 m
Accounts Receivable	2.2 m	1.7 m	1.3 m	727 k	909 k	657 k	1.2 m	1.2 m
Inventories													550 k
Current Assets	79.8 m	181.7 m	160.6 m	134.9 m	102 m	97.9 m	224.3 m	170.7 m	147.1 m	117.5 m	89.7 m	132.2 m	255.4 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(66.7 m)	(90.7 m)	(106.8 m)	(112.4 m)	(95.2 m)
Depreciation and Amortization	1.3 m	1.4 m	1.4 m	2.3 m	3.2 m
Inventories	677 k	(2.7 m)	1.6 m	560 k	(312 k)
Accounts Payable	(657 k)	(523 k)	1.2 m	1.2 m	(1.9 m)

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(15.7 m)	(13.8 m)	(24.8 m)	(29.8 m)	(26.2 m)	(23.6 m)	(30.1 m)	(27 m)	(29 m)	(34.7 m)	(25.3 m)	(39 m)
Depreciation and Amortization												823 k
Inventories												(238 k)
Accounts Payable			1.9 m	5 m	3.3 m	2.3 m	2.4 m	3.5 m	4.5 m	3.8 m	1.5 m	349 k

show all

Ratios

USD	Y, 2018
EV/EBIT	-26.2 x
EV/CFO	-33.6 x
Financial Leverage	1.8 x

Show all financial metrics

Dynavax Technologies Corporation Operating Metrics

	FY, 2016
Patents (foreign)	260
Patents Pending	40
Phase III Trials Products	1
Preclinical Phase Products	2

Show all operating metrics

Dynavax Technologies Corporation Revenue Breakdown

Business Segment

Embed Graph

Dynavax Technologies Corporation revenue breakdown by business segment: 8.0% from Service and license revenue, 88.5% from Collaboration revenue and 3.5% from Other

Report incorrect company information